In one of its partnerships, Gestalt will work to integrate Flagship Bioscience's machine learning tools to enable cancer biomarker detection.
The firms said that their respective technologies are complementary and bridge a technical gap between pathology, radiology, and oncology.
The French company develops software solutions for digital pathology, including software for microscopic and macroscopic image management.
The researchers said that they have demonstrated an approach that skirts a bottleneck and enables building pathology support systems from large datasets.
Inspirata said that the entity will assist hospitals and universities across Europe with data processing, including inter-institutional processing.
With two FDA-cleared platforms available, the technology is drawing clinicians interested in reaping its near-term benefits while preparing for its future impact.
The center will initially use the system for prostate, and head and neck cancers and in the future will let LabCorp patients access Mount Sinai pathologists.
The digital pathology system can be used for primary diagnosis as a result of the 510(k) clearance, which followed a multicenter study conducted at five clinical sites.
The Boston-based company said it will use the funding in part to continue refining its artificial intelligence-powered pathology research platform.
The firms launched OptraScan's Global TelePath Network in the UAE, India, and South Africa under the partnership, named Neuberg Digipath, Powered by OptraScan.